Sibel Elif Gultekin | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Sibel Elif Gultekin | Stem Cell Research | Best Researcher Award

Prof. Dr. Sibel Elif Gultekin, Gazi University Faculty of Dentistry, Turkey

Prof. Dr. Sibel Elif Gültekin is a renowned academic and clinician in Oral Pathology and Periodontology at Gazi University Faculty of Dentistry, Türkiye. With over two decades of experience, she has significantly advanced molecular understanding of odontogenic tumors, HPV-induced oral lesions, and periodontal regeneration. Holding both DDS and Ph.D. degrees, she has led her department as Chair for 10 years and contributed globally as a visiting researcher and advisor. Her collaborations with institutions like the University of Cologne and UCSF reflect her international impact. She has published extensively in high-impact journals, authored books, and mentored numerous young researchers. Her dedication has been recognized through editorial appointments and professional society memberships. Prof. Gültekin’s translational research bridges pathology and clinical dentistry, making her a pioneer in the diagnosis and treatment of oral diseases.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Dual Specialization & Academic Leadership: Prof. Gültekin’s rare dual Ph.D. in Oral Pathology and Periodontology, along with her decade-long leadership as department chair, highlights deep academic and organizational expertise.

  2. High Research Output & Impact: With 96 publications, 50+ research projects, and citations exceeding 1300 (Google Scholar), her scholarly productivity and influence are clear. Her h-index across databases (14–17) confirms consistent academic contribution.

  3. Global Collaborations: Active collaborations with international centers like UCSF and University of Cologne underscore her role in global scientific advancement.

  4. Innovative Research Areas: She works at the forefront of molecular oncology, focusing on HPV-associated oral cancers, odontogenic tumors, and biomarkers like P16, VIM3, and PDCD4.

  5. Educational & Editorial Leadership: Served on scientific and editorial boards, symposiums, and advisory panels; she also authored 2 academic books and guided national congresses.

  6. Professional Societies: Active member of multiple esteemed societies (IAOP, ESP, EHNS, IADR), reflecting recognition in the international scientific community.

⚙️ Areas for Improvement:

  1. Clinical Translation Scaling: While her biomarker discoveries are notable, increasing efforts to lead translational clinical trials could accelerate therapeutic application.

  2. Policy Advocacy: Engaging more in international oral health policy or WHO-affiliated programs could amplify her impact beyond academia.

  3. Mentorship on Global Scale: Expanding formal international mentorship programs or fellowships could further cement her influence and legacy.

🎓 Education:

Prof. Dr. Sibel Elif Gültekin holds both DDS and Ph.D. degrees, specializing in Oral Pathology and Periodontology. She completed her undergraduate dental studies at Gazi University Faculty of Dentistry, where she later pursued her doctoral studies. Her academic training extended beyond Türkiye through international fellowships and research placements, including the prestigious Department of Medicine and Stomatology at the University of California San Francisco (UCSF) and the Institute for Pathology at the University of Cologne. Her educational journey is marked by an interdisciplinary approach, blending basic sciences and clinical applications. These robust academic foundations have positioned her as a global expert in oral cancer biomarkers, regenerative periodontology, and molecular pathology, nurturing future dentists and researchers through an integrative, evidence-based curriculum and global research exposure.

💼 Experience:

Prof. Dr. Gültekin has over 25 years of experience in dentistry, oral pathology, and periodontology. She has served as Professor and Chair of the Department of Oral Pathology at Gazi University, shaping both academic curricula and national diagnostic standards. Internationally, she collaborated with UCSF and the University of Cologne on pioneering projects in oral cancer and HPV research. Her clinical and academic background spans over 50 funded research projects, with 96 published papers in prestigious journals indexed by SCI, Scopus, and PubMed. She has contributed to oral health policy through editorial and advisory roles, including at journals like Journal of Oral Health Frontiers. Her expertise has guided scientific boards and symposia in Türkiye and beyond, particularly in head and neck pathology. She remains a sought-after consultant and reviewer, advocating for personalized medicine and molecular diagnostics in oral health.

🔬 Research Focus:

Prof. Dr. Sibel Elif Gültekin’s research centers on the molecular mechanisms of oral diseases, particularly odontogenic tumors, oral epithelial dysplasia, and HPV-induced carcinomas. She has made key contributions in identifying biomarkers such as P16, PDCD4, VIM3, and CD8+ T-cell infiltrates, enhancing early diagnosis and prognosis of oral and oropharyngeal cancers. Her research also explores microsatellite instability and loss of heterozygosity in oral squamous cell carcinoma. Additionally, she has contributed to periodontal tissue regeneration studies and the development of personalized therapeutic strategies. With over 1,300 citations and an h-index of 17 on Google Scholar, her impactful work bridges molecular science and clinical application. Collaborating with global experts in pathology, oncology, and molecular biology, Prof. Gültekin’s research not only contributes to academic literature but also informs clinical protocols and treatment pathways in modern dentistry and oral oncology.

📚 Publications Top Notes:

  • 🧬 Microsatellite Instability and Loss of Heterozygosity as Prognostic Markers in Oral Squamous Cell Carcinoma (Genes, Chromosomes and Cancer, 2024)

  • 🧪 Efficiency of B-RAF-/MEK-inhibitors in B-RAF Mutated Ameloblastoma: Case Report and Review (Heliyon, 2023)

  • 🦷 Kişiselleştirilmiş Diş Hekimliği (ADO Klinik Bilimler Dergisi, 2023)

  • 🔍 Apoptosis Related PDCD4: Promising Novel Biomarker for Early Detection of Oral Cancer (ADO Klinik Bilimler Dergisi, 2022)

  • 🛡️ PD-L1 Expression and High CD8+ Lymphocyte Infiltrate Predict Outcome in Oropharyngeal SCC (International Journal of Molecular Sciences, 2020)

🧾 Conclusion:

Prof. Dr. Sibel Elif Gültekin is a highly deserving nominee for the Best Researcher Award. Her pioneering contributions in oral pathology, particularly in molecular diagnostics and HPV-related oral oncology, place her at the forefront of dental research. Her exceptional academic record, leadership, and dedication to collaborative and translational science make her a standout candidate who embodies the spirit of innovation, mentorship, and global impact.

Yang Gao | Cell Differentiation Processes | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Yang Gao | Cell Differentiation Processes | Best Researcher Award

Prof. Dr. Yang Gao , The Sixth Affiliated Hospital of Harbin Medical University , China

Professor Yang Gao is the Chief Physician and Director of the Critical Care Medicine Department at The Sixth Affiliated Hospital of Harbin Medical University, China. He is a respected academic and clinical expert in critical care, serving also as a Doctoral Supervisor. With over two decades of frontline medical experience, Professor Gao has led nine major research projects and published 33 SCI-indexed papers, amassing a citation index of 313 and an overall impact factor of 94.493. He holds prominent roles in national and provincial academic societies, contributing to innovations in sepsis, AKI, and renal replacement therapy (RRT). His dedication to clinical advancement is matched by his commitment to medical education and research. Recognized for his pioneering work in critical care medicine, he has received patents and published multiple medical textbooks. His leadership, extensive research contributions, and continued impact on critical care practices make him a strong candidate for the Best Researcher Award.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Extensive Clinical & Research Expertise: With over two decades in frontline critical care, Professor Gao combines clinical acumen with deep research insight, particularly in sepsis-associated acute kidney injury (AKI) and continuous renal replacement therapy (RRT).

  2. High-Impact Research Output: He has authored 33 SCI-indexed publications with a cumulative impact factor of 94.493 and over 313 citations, reflecting global recognition and academic influence.

  3. Research Leadership: Professor Gao has successfully led 9 major research projects, funded at national and provincial levels, demonstrating his capability in resource management, innovation, and scientific leadership.

  4. Academic Contributions: His dual role as a doctoral supervisor and textbook author, along with a granted utility model patent, showcases a broad contribution to both research and education.

  5. Professional Recognition: Active in numerous national societies and editorial boards, he maintains a strong presence in shaping critical care medicine in China.

🔍 Areas for Improvement:

  • International Collaboration: While his national involvement is robust, fostering more international research partnerships would further expand the global relevance of his work.

  • Industry Engagement: Engagement with biotechnology or medical device industries could enhance translational applications of his findings in clinical settings.

🎓 Education:

Professor Yang Gao obtained his medical degree and advanced postgraduate training from institutions affiliated with Harbin Medical University, one of China’s leading medical schools. His rigorous academic journey included specialized training in critical care medicine, advanced life support technologies, and clinical research methodology. During his doctoral studies, he focused on critical illness mechanisms, with an emphasis on sepsis-associated acute kidney injury (AKI). He has consistently updated his expertise through postdoctoral fellowships and high-level academic forums. Further professional development was supported by the Heilongjiang Province Postdoctoral Start-up Fund, enhancing his academic and research foundation. Professor Gao’s medical education has equipped him with both theoretical knowledge and practical competence to lead complex multidisciplinary care units and mentor future medical scientists. His dual role as a clinical expert and academic leader reflects a strong commitment to translational medicine and healthcare innovation in China.

🏥 Experience:

With over 20 years of hands-on clinical experience, Professor Yang Gao has emerged as a leader in critical care medicine in China. Since 2003, he has been managing critically ill patients, mastering life-saving interventions such as non-invasive/invasive ventilation, blood purification, and continuous renal replacement therapy (CRRT). He is the Director of the Critical Care Medicine Department at The Sixth Affiliated Hospital of Harbin Medical University and holds teaching and supervisory roles for doctoral students. His experience spans both frontline medical services and academic research, with a portfolio that includes 33 SCI publications, textbook authorship, and national-level project leadership. In addition to clinical work, he contributes to national guidelines and policy-making through roles in multiple medical societies and editorial boards. Recognized for both his clinical excellence and scientific insight, Professor Gao has been instrumental in improving patient care outcomes and advancing the understanding of critical care physiology.

🔬 Research Focus:

Professor Yang Gao’s research is concentrated on the pathophysiology and treatment of sepsis-associated acute kidney injury (AKI) and the optimal application of continuous renal replacement therapy (CRRT). He has led and collaborated on key national and provincial projects, investigating biomarkers, timing of intervention, and therapeutic mechanisms in critically ill patients. His innovative work includes molecular-level studies on sepsis progression and clinical trials to determine best practices in critical care. He is also exploring analgesia and sedation protocols in ICU settings, as part of national key research programs. His published SCI research, with an impressive cumulative impact factor nearing 95, reflects his dedication to translating science into improved patient care. Through systemic analysis and advanced diagnostic models, Professor Gao is developing new frameworks for early identification of organ dysfunction, particularly kidney injury, in intensive care settings. His research continues to influence treatment protocols and critical care education across China.

📚 Publications Top Notes:

  1. 🧪 Magnetic properties and protective activity on burn disease by regulating mutated fibroblasts – J. Solid State Chem (2021)

  2. 🧫 Role of IL-10 and TNF-α in Sepsis-Induced AKI – Front. Immunol

  3. 🩺 Timing of CRRT in Septic Shock Patients with AKI – Crit Care Med

  4. 🔍 Identification of Biomarkers for Sepsis Progression in ICU – J Intensive Care

  5. 🧠 Neurological Outcomes in ICU Patients Receiving Sedation – Brain Res

  6. 🦠 MicroRNA Profiling in Sepsis-Induced Kidney Damage – Mol Med Rep

  7. 🧬 Effects of Early CRRT on Inflammatory Mediators – Cytokine

  8. 🧴 Pharmacokinetics of Antibiotics in CRRT Patients – Ther Drug Monit

  9. 🧍‍♂️ Prognostic Value of Serum NGAL in AKI Patients – Am J Nephrol

  10. 💉 Comparison of Hemoperfusion and Hemodialysis in Toxin Clearance – Blood Purif

🧾 Conclusion:

Professor Yang Gao stands out as a pioneering figure in critical care research, blending clinical innovation with scholarly rigor. His sustained contributions to understanding and treating sepsis and AKI, along with his strong academic leadership, make him eminently suitable for the Best Researcher Award. Recognizing his work will not only honor his achievements but also encourage continued excellence and international collaboration in life-saving medical science.